首页> 外文期刊>Journal of the American Chemical Society >Ribosomally Synthesized Thiopeptide Antibiotics Targeting Elongation Factor Tu
【24h】

Ribosomally Synthesized Thiopeptide Antibiotics Targeting Elongation Factor Tu

机译:核糖体合成的针对伸长因子Tu的硫肽抗生素

获取原文
获取原文并翻译 | 示例
       

摘要

We identified the thiomuracins, a novel family of thiopeptides produced by a rare-actinomycete bacterium typed as a Nonomuraea species, via a screen for inhibition of growth of the bacterial pathogen Staphylococcus aureus. Thiopeptides are a class of macrocyclic, highly modified peptides that are decorated by thiazoles and defined by a central six-membered heterocyclic ring system. Mining the genomes of thiopeptide-producing strains revealed the elusive biosynthetic route for this class of antibiotics. The thiopeptides are chromosomally encoded, ribosomally synthesized proteins, and isolation of gene clusters for production of thiomuracin and the related thiopeptide GE2270A revealed the post-translational machinery required for maturation. The target of the thiomuracins was identified as bacterial Elongation Factor Tu (EF-Tu). In addition to potently inhibiting a target that is unexploited by marketed human therapeutics, the thiomuracins have a low propensity for selecting for antibiotic resistance and confer no measurable cross-resistance to antibiotics in clinical use.
机译:我们通过抑制细菌病原体金黄色葡萄球菌的生长的筛选,确定了硫菌素,这是一种新型的硫肽家族,由稀有放线菌属细菌被定为诺氏菌属物种产生。硫肽是一类大环的,高度修饰的肽,由噻唑修饰并由中央六元杂环系统定义。挖掘产生硫肽的菌株的基因组揭示了此类抗生素难以捉摸的生物合成途径。硫肽是通过染色体编码,核糖体合成的蛋白质,并分离了用于生产硫菌素的基因簇,相关的硫肽GE2270A揭示了成熟所需的翻译后机制。硫菌素的靶标被鉴定为细菌延伸因子Tu(EF-Tu)。除了有效抑制市售的人类疗法无法利用的靶标外,硫代山mura素还具有低的选择抗生素耐药性的倾向,并且在临床使用中对抗生素没有可测量的交叉耐药性。

著录项

  • 来源
    《Journal of the American Chemical Society》 |2009年第16期|5946-5955|共10页
  • 作者单位

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Infectious Diseases Area;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Analytical Sciences;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Global Discovery Chemistry;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Lead Finding Platform;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Infectious Diseases Area;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Expertise Platform Proteases;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

    Novartis Institutes for BioMedical Research, Basel, 4056, Switzerland, and Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts 02139 Natural Products Unit;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 03:16:53

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号